

Targeting the Hippo-YAP
signaling pathway to
enhance treatment
for patients with
resistant cancer.
ABOUT
At Nivien, we are driven to help people with cancer and other diseases live longer, healthier lives.
We are a startup from the IndieBio Accelerator and Harvard Innovation Labs with a therapeutic strategy based on novel biology from Harvard Medical School.
Our molecules harness the potential of the Hippo-YAP signaling pathway to treat cancer and other indications where Hippo plays an important role. We have patented the first inhibitors of the LATS1/2 kinases and are currently in preclinical testing for several cancers.
Cancer Resistance
Defeating mechanisms that resistant, difficult-to-treat cancers use to evade drug-induced cell death
Tissue Repair
Overcoming irreversible tissue damage such as fibrosis to promote healthier, better-functioning organs
Cardiac Regeneration
Increasing cell proliferation to improve cardiac function after myocardial infarction
NIVIEN

FOUNDERS

ADVISORS

INVESTORS





Contact Us
nathaniel@generalbiotechnologies.com
nikita@generalbiotechnologies.com
Nivien at the IndieBio Accelerator
479 Jessie Street, San Francisco
California, 94103
Nivien at the Harvard Innovation Labs
125 Western Avenue, Boston
Massachusetts, 02163
Read more about Nivien in Forbes:
© 2017 — Nivien Therapeutics Company